NCT00541970 - Partially Blind Study to Evaluate Immunogenicity & Safety of GSK Bio's HPV Vaccine 580299 in Healthy Women Aged 9-25 Yrs | Biotech Hunter

Enrollment

961

Participants

Timeline

Start Date

October 17, 2007

Primary Completion Date

March 18, 2013

Study Completion Date

March 18, 2013

Conditions

Infections, Papillomavirus

Interventions

BIOLOGICAL

Cervarix

Intramuscular injection, different dosing /schedule

DRUG

Placebo

Intramuscular injection, different dosing /schedule

Trial Locations (25)

13086

GSK Investigational Site, Berlin

13125

GSK Investigational Site, Berlin

20246

GSK Investigational Site, Hamburg

22159

GSK Investigational Site, Hamburg

22525

GSK Investigational Site, Hamburg

24937

GSK Investigational Site, Flensburg

30625

GSK Investigational Site, Hanover

30657

GSK Investigational Site, Hanover

38302

GSK Investigational Site, Wolfenbüttel

54290

GSK Investigational Site, Trier

60439

GSK Investigational Site, Frankfurt am Main

76199

GSK Investigational Site, Karlsruhe

76287

GSK Investigational Site, Rheinstetten

77694

GSK Investigational Site, Kehl

80637

GSK Investigational Site, Munich

82362

GSK Investigational Site, Weilheim

97070

GSK Investigational Site, Würzburg

97941

GSK Investigational Site, Tauberbischofsheim

99734

GSK Investigational Site, Nordhausen

T6G 2C8

GSK Investigational Site, Edmonton

V3A 4H9

GSK Investigational Site, Langley

A1E 2C2

GSK Investigational Site, St. John's

B2N 1L2

GSK Investigational Site, Truro

G1E 7G9

GSK Investigational Site, Québec

04109

GSK Investigational Site, Leipzig